News & Updates

Co-administration of piperacillin and tazobactam (PIPC/TAZ) does not result in delayed methotrexate (MTX) clearance during high-dose MTX therapy, a study has shown. In addition, co-administration of cefepime with high-dose MTX had no impact on MTX clearance.

Dual HER-2 inhibition with tucatinib and trastuzumab induces clinically meaningful and durable responses in patients with previously treated metastatic HER2-positive colorectal cancer (mCRC) in the phase II MOUNTAINEER trial, boosting hopes for this chemotherapy-free combination.

Implementing a clinical pharmacist-led service program has led to the standardization and streamlining of refractory chemotherapy-induced nausea and vomiting (CINV) management in adult haematology and oncology clinics, reports a study.

The real-world effectiveness of eribulin in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer is lower than that seen in clinical trials, reveals a study.

Researchers have recently created a core outcome set for basal cell carcinoma clinical trials.

Despite prior evidence of excellent actinic keratosis (AK) destruction efficacy, 5-fluorouracil (5-FU) does not appear to be better than imiquimod in the prevention of cutaneous squamous cell carcinoma (cSCC), reports a recent study.